🚀 VC round data is live in beta, check it out!
Theravance Valuation Multiples
Discover revenue and EBITDA valuation multiples for Theravance and similar public comparables like Sanofi India, Basilea Pharmaceutica, Bright Minds Biosciences, Marksans Pharma and more.
Theravance Overview
About Theravance
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Founded
2013
HQ
Employees
97
Website
Financials (LTM)
EV
$615M
Theravance Financials
Theravance reported last 12-month revenue of $110M.
In the same LTM period, Theravance generated $110M in gross profit and $116M in net income.
Revenue (LTM)
Theravance P&L
In the most recent fiscal year, Theravance reported revenue of $107M and EBITDA of $135M.
Theravance expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $107M | XXX | XXX | XXX |
| Gross Profit | $110M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | $135M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 125% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | (3%) | XXX | XXX | XXX |
| Net Profit | $116M | XXX | $106M | XXX | XXX | XXX |
| Net Margin | 105% | XXX | 99% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Theravance Stock Performance
Theravance has current market cap of $887M, and enterprise value of $615M.
Market Cap Evolution
Theravance's stock price is $17.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $615M | $887M | 0.0% | XXX | XXX | XXX | $2.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTheravance Valuation Multiples
Theravance trades at 5.6x EV/Revenue multiple, and 4.6x EV/EBITDA.
EV / Revenue (LTM)
Theravance Financial Valuation Multiples
As of April 20, 2026, Theravance has market cap of $887M and EV of $615M.
Equity research analysts estimate Theravance's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Theravance has a P/E ratio of 7.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $887M | XXX | $887M | XXX | XXX | XXX |
| EV (current) | $615M | XXX | $615M | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | 40.7x | XXX | (170.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | — | XXX | XXX | XXX |
| P/E | 7.6x | XXX | 8.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Theravance Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Theravance Margins & Growth Rates
Theravance's revenue in the last 12 month declined by (2%).
Theravance's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.1M for the same period.
Theravance Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (2%) | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 125% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (450%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 60% | XXX | 69% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 103% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Theravance Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Theravance | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| Basilea Pharmaceutica | XXX | XXX | XXX | XXX | XXX | XXX |
| Bright Minds Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Marksans Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theravance M&A Activity
Theravance acquired XXX companies to date.
Last acquisition by Theravance was on XXXXXXXX, XXXXX. Theravance acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Theravance
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTheravance Investment Activity
Theravance invested in XXX companies to date.
Theravance made its latest investment on XXXXXXXX, XXXXX. Theravance invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Theravance
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Theravance
| When was Theravance founded? | Theravance was founded in 2013. |
| Where is Theravance headquartered? | Theravance is headquartered in United States. |
| How many employees does Theravance have? | As of today, Theravance has over 97 employees. |
| Who is the CEO of Theravance? | Theravance's CEO is Rick E. Winningham. |
| Is Theravance publicly listed? | Yes, Theravance is a public company listed on Nasdaq. |
| What is the stock symbol of Theravance? | Theravance trades under TBPH ticker. |
| When did Theravance go public? | Theravance went public in 2014. |
| Who are competitors of Theravance? | Theravance main competitors are Sanofi India, Basilea Pharmaceutica, Bright Minds Biosciences, Marksans Pharma. |
| What is the current market cap of Theravance? | Theravance's current market cap is $887M. |
| What is the current revenue of Theravance? | Theravance's last 12 months revenue is $110M. |
| What is the current revenue growth of Theravance? | Theravance revenue growth (NTM/LTM) is (2%). |
| What is the current EV/Revenue multiple of Theravance? | Current revenue multiple of Theravance is 5.6x. |
| Is Theravance profitable? | Yes, Theravance is net-income-positive (as of the last 12 months). |
| What is the current net income of Theravance? | Theravance's last 12 months net income is $116M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.